NCT06308419 2026-02-25
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
M.D. Anderson Cancer Center
Phase 1 Recruiting
Clinical Trials
14 trialsNCT04807816 2025-10-02
TARSARC
Institut Bergonié
Phase 2 Recruiting
NCT04535271 2025-02-24
TAGGED
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT02203760 2024-11-15
PazoDoble
North Eastern German Society of Gynaecological Oncology
Phase 2 Active not recruiting
NCT05116800 2021-12-07
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
Phase 2 Withdrawn
NCT01532687 2021-09-27
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT04906876 2021-07-28
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Brown University
Phase 2 Withdrawn
NCT01442662 2020-01-31
LMS03
UNICANCER
Phase 2 Completed
NCT02249702 2017-12-06
TAUL
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT00227669 2016-08-30
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
UNICANCER
Phase 2 Completed
NCT00887809 2016-01-25
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01426633 2014-12-16
Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
Heidelberg University
Phase 1 Completed
NCT00282087 2014-12-01
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00004066 2013-03-07
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed